Fresenius Medical Care AG & Co. KGaA (FME) PT Set at €100.00 by Deutsche Bank

Share on StockTwits

Fresenius Medical Care AG & Co. KGaA (ETR:FME) received a €100.00 ($116.28) price target from Deutsche Bank in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s target price would indicate a potential upside of 48.10% from the stock’s current price.

A number of other equities research analysts have also commented on the company. UBS Group set a €82.00 ($95.35) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Friday, October 26th. JPMorgan Chase & Co. set a €97.90 ($113.84) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Tuesday, October 30th. Goldman Sachs Group set a €89.00 ($103.49) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research report on Friday, December 7th. Commerzbank set a €79.00 ($91.86) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research report on Friday, December 7th. Finally, Cfra set a €78.00 ($90.70) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a “neutral” rating in a research report on Wednesday, October 17th. Nine investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of €82.75 ($96.22).

ETR FME opened at €67.52 ($78.51) on Tuesday. Fresenius Medical Care AG & Co. KGaA has a one year low of €75.53 ($87.83) and a one year high of €93.82 ($109.09).

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Read More: Stochastic Momentum Index (SMI)

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply